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(CHF).Background Qili qiangxin capsules are a traditional Chinese medicine that has been approved in China for the treatment of CHF,
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or percent change in the plasma N-terminal pro–B-type natriuretic peptide (NT-proBNP) level during 12 weeks of
treatment.Results At the 12-week follow-up, a signiﬁcant reduction in the NT-proBNP level from baseline was observed in both groups,
but the qili qiangxin capsule group demonstrated a signiﬁcantly greater reduction than the placebo group
(p ¼ 0.002); 47.95% of patients in the qili qiangxin capsule group demonstrated reductions in NT-proBNP levels
of at least 30% compared with 31.98% of patients in the placebo group (p < 0.001). Treatment with qili qiangxin
capsules also demonstrated superior performance in comparison to the placebo with respect to New York Heart
Association functional classiﬁcation, left ventricular ejection fraction, 6-min walking distance, and quality of life.Conclusions On a background of standard treatment, qili qiangxin capsules further reduced the levels of NT-proBNP. Together,
our data suggest that qili qiangxin capsules could be used in combination therapy for CHF. (J Am Coll Cardiol
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drug treatment strategy for heart
failure, the number of deaths re-
sulting from this condition con-
tinues to rise.
From the perspective of tradi-
tional Chinese medicine (TCM),
the primary cause of heart failure is
heart Yang deﬁciency that results
from Qi inadequacy and blood
stasis. Some Chinese herbs have
demonstrated safety and efﬁcacy
in the management of heart fai-
lure in either animal models or
humans (5–8). Qili qiangxin
capsules are a speciﬁc TCMpage 1073extract obtained from 11 types of herbs, including astragali
radix, ginseng radix et rhizoma, aconiti lateralis radix pre-
parata, Salvia miltiorrhiza radix et rhizoma, semen descur-
ainiae lepidii, alismatis rhizoma, polygonati odorati rhizoma,
cinnamomi ramulus, carthami ﬂos, periploca cortex, and citri
reticulatae pericarpium. Astragali radix and aconiti lateralis
radix preparata are the principal pharmacologically active
components. Qili qiangxin capsules were approved by China
Food and Drug Administration for the treatment of heart
failure in 2004.
The current study evaluated the effects of qili qiangxin
capsules in patients with CHF. The primary endpoint was
the plasma N-terminal pro–B-type natriuretic peptide (NT-
proBNP) level, and the secondary endpoints consisted of
composite cardiac events (CCEs), New York Heart Asso-
ciation (NYHA) functional classiﬁcation, 6-min walking
distance (6MWD), echocardiographic measures, and patient
quality of life.Methods
Design and eligibility. Theprimaryobjectiveof this studywas
to assess whether qili qiangxin capsules were superior to a placebo
for CHF treatment. This study was designed as a multicenter,
randomized, double-blind, placebo-controlled study based on
standard therapy and parallel groups. The target enrollment was
512 patients at 23 clinical research centers in China. The
enrollment criteria consisted of patients aged 18 to 75 years and
clinical ﬁndings of CHF for at least 3 months prior to screening.
Both men and women were included. CHF was diagnosed
according to the Chinese guidelines published in 2007 for the
diagnosis and management of CHF (5). The patients were
clinically stable, had an NYHA functional class of II to IV, and
had received optimalmedical treatment with a ﬁxed dosage for at
least 2 weeks. To be included in this trial, patients had to have a
documented left ventricular ejection fraction (LVEF)40% anda serumNT-proBNP level450 pg/ml. Patients were excluded
if CHF was caused by valvular disease, congenital heart disease,
pericardial disease, cardiac arrhythmia, or other noncardiogenic
factors. In addition, patients were excluded if they were likely to
undergo coronary artery bypass graft surgery during the following
12 weeks; had undergone or were likely to undergo cardiac
resynchronization therapy; had uncorrected primary valvular
disease, left ventricular outﬂow obstruction, myocarditis, aneu-
rysm, uncontrolled severe arrhythmia, cardiogenic shock,
unstable angina, or acute myocardial infarction; had severe
primary hepatic, renal, or hematologic disease; or had a severe
mental health condition or other uncontrolled systemic disease.
Finally, patientswere excluded if theyhad a serumcreatinine level
>194.5 mmol/l or serum potassium level >5.5 mmol/l; had
alanine aminotransferase or alkaline phosphatase levels >1.5
times the upper normal limit; had uncontrolled blood pressure,
with a systolic blood pressure180 mmHg or a diastolic blood
pressure110 mmHg; were pregnant or lactating; were known
or suspected to be allergic to the studydrugs; had received another
investigational drug within 30 days prior to randomization; or
were unwilling or unable to provide written consent.
Study protocol. In this double-blind trial, patients were
evaluated based on self-reported history, physical examina-
tions, laboratory screening, and transthoracic Doppler
echocardiography. Eligible patients were randomly assigned
to 2 groups that received either qili qiangxin capsules or
a placebo (in a 1:1 ratio; the treatments were provided as
capsules that were identical in size and shape) in addition to
their usual care or medications prescribed for CHF by the
attending physicians. The study medication was labeled with
sequential randomization numbers, and each patient was
assigned the lowest number available at each site at the
randomization visit. The dosage used in this study was 4
capsules of qili qiangxin or placebo 3 times daily. Patients
attended follow-up appointments at the fourth, 8th, and
12th weeks of treatment. At each visit, patients were asked
about the occurrence of any clinical event or adverse effect;
in addition, symptoms were reviewed, vital signs were
measured, and the dose of the study drug was recorded.
At each visit, the participants were required to complete
the Minnesota Living With Heart Failure Questionnaire
(MLHFQ), one of the most widely used questionnaires to
assess heart failure. Echocardiography and the 6MWD test
were performed at baseline and at the last visit. LVEF was
estimated using the biplane Simpson method. The entire
study period lasted 12 weeks.
The study protocol was reviewed and approved by the
appropriate independent ethics committees. All participants
provided written informed consent, and the study was
conducted in accordance with the principles of Good
Clinical Practice and the Declaration of Helsinki. The trial
was registered at ChiCTR-TRC-11001478.
Laboratory tests. Routine laboratory tests (complete blood
count, urinalysis, and serum chemistry proﬁle) were performed
in the local laboratories of the participating institutions. The
Figure 1 Flow Diagram Illustrating the Number of Patients in Each Group Throughout the Study
FAS ¼ full analysis set.
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1067estimated glomerular ﬁltration rate was calculated according
to the modiﬁed estimated glomerular ﬁltration rate equation
for Chinese patients (9). Plasma NT-proBNP levels were
measured in the Department of Laboratory Medicine, First
Afﬁliated Hospital of Nanjing Medical University, Nanjing,
China, using dedicated kit-based NT-proBNP assays (Roche
Diagnostics, Basel, Switzerland).
Endpoints. The primary endpoint was either the percent
reduction in plasma NT-proBNP level or the proportion of
patients in the qili qiangxin capsule group relative to the
placebo group demonstrating a decrease in NT-proBNP level
of at least 30%. The secondary endpoints included CCEs,
NYHA classiﬁcation, 6MWD test results, echocardiographic
measures, and quality of life. CCEs were deﬁned as death,
cardiac arrest with resuscitation, re-admission for heart
failure, worsening heart failure with an intravenous phar-
macological agent for more than 4 h, stroke, or cases in which
the patient ceased active treatments because of worsening
heart failure. The assessments of safety and tolerability were
based on spontaneous reports of adverse events, vital signs,
and laboratory measurements.
Sample size calculation. The sample size was calculated
based on the expected reduction in plasmaNT-proBNP levels
from pre- to post-treatment. A previous study suggested that
the prognosis of patients whose NT-proBNP levels decreased
by at least 30% from baseline with therapy was signiﬁcantly
better than for patients with no signiﬁcant change or an
increase in NT-proBNP levels (10). Therefore, assuming
a 38% reduction in plasma NT-proBNP level following-
treatment with qili qiangxin capsules (i.e., 30% greaterreduction than basic therapy), and given a type I error rate of
alpha¼ 0.05, a power of 80% (type II error rate of beta¼ 0.2),
and the normal SD of 30%, the sample size for 1 arm needed
to be 175, resulting in n¼ 2 175¼ 350 patients.Moreover,
considering a dropout rate of approximately 20% among
randomized patients, a total of 420 patients (210 per treat-
ment group) needed to be randomized to achieve the required
number of patients for the efﬁcacy analysis.
The sample size was also calculated based on the expected
proportion of patients demonstrating an NT-proBNP level
decrease of at least 30%. According to previous clinical
results, we assumed the proportion of patients demonstrating
a decrease in NT-proBNP level of at least 30% in the placebo
group would be 40%, 12% lower than the tested group.
Therefore, given a type I error rate of alpha¼ 0.05, a power of
80% (type II error rate of beta ¼ 0.2), the sample size for 1
arm needed to be 213, resulting in n ¼ 2  213 ¼ 426
patients. Moreover, considering a dropout rate of approxi-
mately 20% for randomized patients, a total of 512 patients
(256 per treatment group) needed to be randomized to ach-
ieve the required number of patients for the efﬁcacy analysis.
Under these 2 assumptions, we recruited 512 patients to
the study, who were subsequently allocated at a 1:1 ratio to
the qili qiangxin capsule group or the placebo group.
Statistical analysis. All statistical analyses were performed
with SAS software, version 9.2 (SAS Institute, Cary,
North Carolina). Data from all patients who underwent
randomization were analyzed according to the full analysis
set principle. Continuous variables are presented as the
mean  SD. The comparability of the characteristics
Table 1 Baseline Characteristics of Patients Receiving Qili Qiangxin Capsules or Placebo
Characteristic
Qili Qiangxin Capsules
(n ¼ 244)
Placebo
(n ¼ 247)
All
(N ¼ 491)
Course of disease, months 77.25  10.94 77.14  11.27 77.20  11.10
Demographics
Age, yrs 56.98  11.59 57.53  11.05 57.25  11.31
Male 74.59 76.11 75.36
Race
Han 98.77 98.79 98.78
Other 1.23 1.21 1.22
Measurements
Weight, kg 68.63  12.32 68.80  13.05 68.72  12.68
Height, cm 167.28  7.71 167.13  7.06 167.20  7.39
Systolic BP, mm Hg 120.44  16.43 120.42  17.18 120.43  16.80
Diastolic BP, mm Hg 77.25  10.94 77.14  11.27 77.20  11.10
Heart rate, beats/min 78.41  13.69 77.84  13.36 78.12  13.51
Etiology of CHF
Cardiomyopathy 58.61 55.06 56.82
Ischemic heart disease 31.56 33.60 32.59
Hypertension 16.80 22.67 19.76
Other* 0.82 3.64 2.24
Medical history
Atrial ﬁbrillation 14.34 16.60 15.48
Diabetes mellitus 13.93 19.43 16.7
Medication
ACE inhibitors 169 (69.26) 157 (63.56) 326 (66.40)
Angiotensin receptor blockers 51 (20.90) 48 (19.43) 99 (20.16)
Beta-blockers 191 (78.28) 196 (79.35) 387 (78.82)
Aldosterone antagonists 190 (77.87) 201 (81.38) 391 (79.63)
Diuretics 220 (90.16) 222 (89.88) 442 (90.02)
Digoxin 127 (52.05) 136 (55.06) 263 (53.56)
NYHA functional class
I 0 0 0
II 52.46 53.44 52.95
III 41.80 41.70 41.75
IV 5.74 4.86 5.3
Echocardiography measurements
LVEF, % 31.85  6.41 31.86  6.46 31.85  6.43
LVED, mm 66.54  10.13 66.63  10.67 66.59  10.39
Laboratory measurements
Sodium, mmol/l 139.86  3.84 139.78  3.78 139.82  3.80
Potassium, mmol/l 4.30  0.57 4.33  0.61 4.31  0.59
Creatinine, mmol/l 84.40  25.01 89.85  40.21 87.19  33.73
eGFR, ml/min/1.73 m2y 97.22  57.39 91.31  34.00 94.20  46.95
Hemoglobin, g/l 140.95  18.39 139.70  18.76 140.32  18.57
Plasma NT-ProBNP, pg/ml 3,204.36  4,260.22 3,224.64  4,985.90 3,214.56  4,634.77
Median (Q1, Q3) 1,818.00 (910.45, 3,613.50) 1,815.00 (973.60, 3,172.00) 1,815.00 (962.30, 3,327.00)
6MWD, m 376.57  98.39 350.85  82.43 363.64  91.40
MLHFQ 34.91  17.67 35.48  17.22 35.20  17.43
Values are mean  SD , %, n (%), or median (Q1, Q3). *Statistically signiﬁcant at p < 0.05 (qili qiangxin capsule group vs. placebo group). yEstimated glomerular ﬁltration rate
(eGFR; ml/min/1.73 m2) ¼ 175  creatinine1.234  age0.179  0.79 (if female); creatinine levels in mmol/l can be converted to mg/dl by dividing them by 88.4.
6MWD ¼ 6-min walking distance; ACE ¼ angiotensin-converting enzyme; BP ¼ blood pressure; CHF ¼ chronic heart failure; LVED ¼ left ventricular end-diastolic diameter;
LVEF ¼ left ventricular ejection fraction; MLHFQ ¼ Minnesota Living With Heart Failure Questionnaire; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York
Heart Association.
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1068between the 2 study groups was assessed using a 2-sample
Student t test for continuous variables and the chi-square
test or Wilcoxon test, when appropriate, for categorical
variables. The Wilcoxon paired signed-rank test was used
for within-group comparisons. Values of < 0.05 were
considered statistically signiﬁcant, and all tests were 2 tailed.Results
From September 2011 to July 2012, 512 patients
underwent randomization at 23 sites in China; the ﬂow
diagram of patients through the study is presented in
Figure 1. The baseline characteristics of the study groups
Table 2 Change in Plasma NT-ProBNP Levels From Baseline to After 12 Weeks of Follow-Up
Qili Qiangxin Capsules (n ¼ 244) Placebo (n ¼ 247) p Value
Difference in NT-proBNP,
pg/ml
240.15 (23.15, 1,113.85) 0.00 (286.00, 800.00) 0.002
Median percent reduction
in NT-proBNP, %
24.70 (1.55, 63.70) 0.00 (18.08, 43.79) <0.001
Proportion of patients with
reduction in
NT-proBNP of 30%, %
47.95 31.98 <0.001
Values are the median (Q1, Q3) or the % of patients. Difference in NT-proBNP ¼ baseline level  12-week level. Percent reduction in NT-proBNP ¼
(baseline level  12-week level)/baseline level  100%.
Abbreviation as in Table 1.
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1069are shown in Table 1. The mean age of the total pop-
ulation was 57.25 years, and 75.36% were male. The
average course of CHF was 77.2 months. The CHF
etiologies included cardiomyopathy (56.82%), ischemic
heart disease (32.59%), hypertension (19.76%), and other
conditions (2.24%). The distributions of the demographic
and clinical characteristics between the qili qiangxin
capsule group and the placebo group were well balanced
and homogeneous.
Change in plasma NT-proBNP level. A favorable effect
of qili qiangxin capsules was observed on the plasma
NT-proBNP level (Table 2). After 12 weeks of treat-
ment, both groups showed a signiﬁcant decrease in NT-
proBNP levels from baseline, but treatment with qili
qiangxin capsules led to a signiﬁcantly greater reduction
than did the placebo (240.15 pg/ml [Q1, Q3: 23.15,
1,113.85]) vs. 0.00 pg/ml [Q1, Q3: 286.00, 800.00];
p ¼ 0.002). The mean percent reductions in NT-proBNP
level for the qili qiangxin capsule and placebo groups were
24.70% (Q1, Q3: 1.55%, 63.70%) and 0.00% (Q1, Q3:
18.08%, 43.79%) (p < 0.001), respectively. A total of
47.95% of the patients in the qili qiangxin capsule group
had reductions in NT-proBNP levels of at least 30%,
compared with 31.98% of patients in the placebo group
(p < 0.001).
CCEs. Table 3 presents the rates of CCEs for both groups.
Overall, 4.51% and 10.93% of patients in the qili qiangxin and
placebo groups experienced CCEs, respectively (p ¼ 0.008).
NYHA functional classiﬁcation. The NYHA class was
determined at each visit. As shown in Figure 2, there was no
difference between the 2 groups at baseline. The frequencyTable 3 CCEs of Patients Receiving Qili Qiangxin
CCEs*
Death
Cardiac arrest with resuscitation
Re-admission for HF
Worsening HF with an intravenous pharmacological agent
Stroke
Patient abandonment for worsening HF
Values are n (%). Some patients reported more than 1 event. *Statistically s
CCE ¼ composite cardiac event(s); HF ¼ heart failure.of NYHA I patients gradually increased, whereas the
frequency of NYHA III to IV patients gradually decreased
after treatment with either qili qiangxin capsules or placebo
accompanied by background treatment. In this analysis, qili
qiangxin capsule treatment resulted in superior improve-
ments at the 8- and 12-week visits compared with the
placebo (p ¼ 0.005 and p < 0.001, respectively).
Echocardiography measurements and 6MWD. At base-
line and at the 12-week visit, echocardiography and the
6MWD test were performed. As shown in Table 1, the pa-
rameters of the echocardiography measurements and
the 6MWDdid not differ between the 2 groups at baseline, and
great improvement was observed after treatment with either qili
qiangxin capsules or placebo accompanied by the background
therapy at the 12-week visit (p < 0.001 for all) (Fig. 3).
Compared with patients randomized to the placebo treatment
group, patients receiving qili qiangxin capsule treatment
exhibited greater improvements in LVEF and 6MWD (p ¼
0.001; 95% CI: 0.03 to 0.15 and p¼ 0.006; 95% CI:0.03 to
0.13, respectively) but not in left ventricular end-diastolic
diameter (p ¼ 0.519; 95% CI: 0.04 to 0.01).
Quality of life assessment using the MLHFQ. The
MLHFQ was completed at each visit, and the 2 groups
demonstrated similar mean MLHFQ scores at baseline
(Table 1). Overall, there was a gradual improvement in the
mean MLHFQ score during the entire treatment period,
and signiﬁcant effects of qili qiangxin capsule treatment
compared with placebo were observed at the 4-, 8-, and 12-
week visits (p < 0.001 for all), as shown in Figure 4.
Adverse events. A total of 250 patients in each group were
included in the safety set analyses (Table 4). The totalCapsule Therapy or Placebo
Qili Qiangxin Capsules (n ¼ 244) Placebo (n ¼ 247)
n ¼ 11 (4.51%) n ¼ 27 (10.93%)
4 (1.64) 7 (2.83)
0 1 (0.40)
8 (3.28) 16 (6.48)
0 2 (0.81)
1 (0.41) 1 (0.40)
0 1 (0.40)
igniﬁcant at p ¼ 0.008.
Figure 2 NYHA Functional Classiﬁcation Results
(A) Qili qiangxin capsule group. (B) Placebo group. NYHA ¼ New York Heart Association.
Figure 3 Echocardiography Measurements and 6MWD Changes From Baseline to After 12 Weeks of Treatment
Values are expressed as mean  SD. The mean rate of change ([12-week level  baseline level]/baseline level) of (A) left ventricular ejection fraction (LVEF), (B) left ventricular
end-diastolic diameter (LVED), and (C) 6-min walking distance (6MWD) test.
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Figure 4
Percent Change in the MLHFQ Scores From
Baseline Through 12 Weeks of Follow-Up
MLHFQ ¼ Minnesota Living With Heart Failure Questionnaire.
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1071number of adverse events was 66 in the qili qiangxin capsule
group versus 98 in the placebo group (p ¼ 0.122); for serious
adverse events, the total number was 12 in the qili qiangxin
capsule group versus 22 in the placebo group (p ¼ 0.103).
Some patients reported more than 1 event. There was no
report of any serious adverse events related to the study drugs.
The analysis of drug-induced adverse events and withdrawal
revealed no differences between the study groups.Discussion
CHF is clinically associated with high mortality, high
morbidity, decrease in quality of life, and substantial burden
on health care systems. The purpose of diagnosing and
treating CHF is to reduce patient mortality and morbidity
(3). The prognosis for patients with CHF has improved in the
past 2 decades, largely because of the use of neurohormonalTable 4 Summary of Adverse Events
Qili Qiangxin Capsules (n ¼ 250)
n (Case) %
AEs 55 (66) 22.00
AEs related to study drugs 19 (20) 7.60
SAEs 12 (12) 4.80
Death* 4 2.00
Hospitalization
Arterial occlusive diseases 0 0
Worsening heart failure 4 1.6
Stroke 1 0.40
Lumbar fracture 1 0.40
Unknown reason 2 0.80
Withdrew due to study drugs 15 (14) 5.60
The analysis included all patients who received at least 1 dose of the study medication. Some patients
analysis set analysis.
AE ¼ adverse event(s); SAE ¼ serious adverse event(s).antagonists such as angiotensin-converting enzyme inhibi-
tors, beta-blockers, and aldosterone antagonists, but the
prognosis remains poor. It is therefore crucial to develop
novel therapeutic approaches for the treatment of CHF.
Qili qiangxin is a widely used TCM for the treatment of
CHF, and its efﬁcacy against cardiac hypertrophy and
remodeling has been demonstrated in several studies. Xiao
et al. (11) investigated the effects of qili qiangxin powder on
cardiac function in rats with myocardial infarction and found
that qili qiangxin treatment signiﬁcantly improved cardiac
function and histopathologic changes, with a down-
regulated ratio of tumor necrosis factor alpha/interleukin
10. One possible mechanism underlying the beneﬁcial
effects of qili qiangxin may involve the regulation of the
balance between proinﬂammatory and anti-inﬂammatory
cytokines in cardiomyocytes (11). In addition, Liu et al.
(12) found that the original superﬁne qili qiangxin powder
improved both systolic and diastolic cardiac function in
spontaneously hypertensive rats by down-regulating the
cardiac chymase signaling pathway and chymase-mediated
angiotensin II production. Zou et al. (13) examined the
effects of qili qiangxin powder on the development of cardiac
hypertrophy in mice with underlying transverse aorta
constriction and found that qili qiangxin inhibited myocar-
dial inﬂammation and cardiomyocyte death and promoted
cardiomyocyte proliferation, leading to improved cardiac
remodeling and cardiac function. The mechanisms of qili
qiangxin may involve inhibition of the angiotensin II type 1
receptor and activation of ErbB receptors (13). (A mini-
review is provided in the Online Appendix).
NT-proBNP, a biologically inactive fragment of BNP, is
released by the heart in response to myocardial tension and
increased intravascular volume. Elevated levels of circulating
NT-proBNP assist in the diagnosis of heart failure and are
associated with increased mortality and morbidity in patients
with heart failure (14–16). Moreover, NT-proBNP can be
accurately measured in the laboratory, and the magnitudePlacebo (n ¼ 250)
p Valuen (Case) %
71 (98) 28.40 0.122
23 (23) 9.20 0.629
21 (22) 8.40 0.103
9 3.60
1 0.40
7 2.8
1 0.40
0 0
3 1.20
17 (17) 6.80 0.711
reported more than 1 event. *Two dead patients in the placebo group were not included in the full
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1072of change can be used as an endpoint for clinical trials
focused on heart failure. The results of our study suggest that
qili qiangxin capsules can markedly reduce NT-proBNP
levels, which suggests that patients may receive an
improved prognosis with long-term treatment. However,
a large, randomized, controlled study using all-cause
mortality as the endpoint is needed to test this hypothesis.
The CCE results indicated favorable effects of qili
qiangxin capsules, and fewer deaths and re-admissions for
heart failure were observed in the qili qiangxin capsule
group compared with the placebo group; however, these
differences were not signiﬁcant. Our results also showed
that qili qiangxin capsules improved exercise tolerance and
patient quality of life and resulted in improvements in
both the NYHA functional class and echocardiography
measurements.
Conclusions
On a background of standard treatment, qili qiangxin cap-
sules further reduced the levels of NT-proBNP. Together,
our data suggest that qili qiangxin capsules could be used in
combination therapy for CHF.
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APPENDIX
For a supplemental mini-review of qili qiangxin capsules and a list of sites
and staff that participated in this study, please see the online version of this
article.
